Drug Duo May Be a Weapon Against a Common Leukemia August 1, 2019 by vowcorp The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia (CLL) found that a combination of rituximab and ibrutinib extended patient survival. Source: Medical News